Utolsó frissítés :
03/05/2024
Fájdalomcsillapító   Morphine sulfate  
Injekció
Belsőleges oldat Kenőcs
Az oldatok stabilitása A keverékek stabilitása Stabilitást befolyásoló tényezők Kompatibilitás Az alkalmazás módja Irodalom Pdf
   Kémiai szerkezet   

Kereskedelmi név   Kereskedelmi név     

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Dimor F Brazília
Duramorph Amerikai Egyesült Államok
Infumorph Amerikai Egyesült Államok
Miniject Morphine Nagy-Britannia
Morphine Kanada
Morphine sulfate Lavoisier Franciaország
Irodalom   Injekció   Irodalom : Morphine sulfate  
Type Publikáció
3 Napló Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
6 Napló Trissel LA, Xu QA, Martinez JF, Fox JL.
Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C.
Am J Hosp Pharm 1994 ; 51: 2138-2142.
8 Napló Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER.
Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 368-371.
57 Napló Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
58 Napló Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161.
59 Napló Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62 Napló Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
64 Napló DiStefano JE, Outman WR.
Additional data on visual compatibility of foscarnet sodium with morphine sulfate.
Am J Hosp Pharm 1992 ; 49: 1672.
65 Napló Duafala ME, Kleinberg ML, Nacov C, Flora KP, Hines J, Davis K, McDaniel A, Scott D.
Stability of morphine sulfate in infusion devices and containers for intravenous administration.
Am J Hosp Pharm 1990 ; 47: 143-146.
73 Napló Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
81 Napló Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Napló Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
86 Napló Johnson CE, Bhatt-Mehta V, Mancari SC, McKown JA.
Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration.
Am J Hosp Pharm 1994 ; 51: 2812-2815.
91 Napló Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
93 Napló Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99 Napló Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
115 Napló Nahata MC, Morosco RS, Hipple TF.
Stability of morphine sulfate in bacteriostatic 0.9% sodium chloride injection stored in glass vials at two temperatures.
Am J Hosp Pharm 1992 ; 49: 2785-2786.
116 Napló Stiles ML, Tu YH, Allen LV Jr.
Stability of morphine sulfate in portable pump reservoirs during storage and simulated administration.
Am J Hosp Pharm 1989 ; 46: 1404-1407.
117 Napló Vecchio M, Walker SE, Iazzetta J, Hardy BG.
The stability of morphine intravenous infusion solutions.
Can J Hosp Pharm 1988 ; 41: 5-9.
119 Napló Strong ML, Schaaf LJ, Pankaskie MC, Robinson DH.
Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices.
J Clin Pharm Ther 1994 ; 19: 361-369.
120 Napló Walker SE, Coons C, Matte D, DeAngelis C, Iazzetta J, Kolos C, Birkhans B.
Hydromorphone and morphine stability in portable infusion pump cassettes and minibags.
Can J Hosp Pharm 1988 ; 41: 177-182.
121 Napló Walker SE, Iazzetta J, Lau DWC.
Stability of sulfite free high potency morphine sulfate solutions in portable infusion pump cassettes.
Can J Hosp Pharm 1989 ; 42: 195-200.
122 Napló Grassby PF, Hutchings L.
Factors affecting the physical and chemical stability of morphine sulphate solutions stored in syringes.
Int J Pharm Pract 1993 ; 2: 39-43.
129 Napló Smythe M, Malouf E.
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Am J Hosp Pharm 1991 ; 48: 125-126.
169 Napló Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Napló Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
198 Napló Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
199 Napló Hassan E, Leslie J, Martir-Herrero ML.
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 2143-2145.
218 Napló Vogt C, Ruggaber S.
Compatibility of magnesium sulfate and morphine sulfate in 0.9% sodium chloride injection.
Am J Hosp Pharm 1993 ; 50: 2311.
220 Napló Johnson CE, Christen C, Perez MM, Ma M.
Compatibility of bupivacaine hydrochloride and morphine sulfate.
Am J Health-Syst Pharm 1997 ; 54: 61-64.
221 Napló Neels JT.
Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate.
Am J Hosp Pharm 1992 ; 49: 2149.
240 Napló Lam XM, Ward CA, de C du M?e CPR.
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy.
Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
244 Napló Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Napló Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Napló Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Napló Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Napló Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
257 Napló Hunt-Fugate AK, Hennessey CK, Kazarian CM.
Stability of fluconazole in injectable solutions.
Am J Hosp Pharm 1993 ; 50: 1186-1187.
266 Napló Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
295 Napló Yamashita SK, Walker SE, Choudhury T, Iazzetta J.
Compatibility of selected critical care drugs during Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299 Napló Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Napló Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Napló Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Napló Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
314 Napló Chiu MF, Schwartz ML.
Visual compatibility of injectable drugs used in the intensive care unit.
Am J Health-Syst Pharm 1997 ; 54: 64-65.
315 Napló Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316 Napló Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
319 Napló Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999.
334 Napló Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Napló Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 Napló Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Napló Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
340 Napló Macias JM, Martin WJ, Lloyd CW.
Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation.
Am J Hosp Pharm 1985 ; 42: 1087-1094.
341 Napló Baker DE, Yost GS, Craig VL, Campbell RK.
Compatibility of heparin sodium and morphine sulfate.
Am J Hosp Pharm 1985 ; 42: 1352-1355.
386 Napló Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
398 Napló Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
402 Napló Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
404 Napló Forman JK, Souney PF.
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
Am J Hosp Pharm 1987 ; 44: 2298-2299.
405 Napló Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
406 Napló Smythe MA, Patel MA, Gasloli RA.
Visual compatibility of narcotic analgesics with selected intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 819-820.
492 Napló Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Napló Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
513 Napló Xu QA, Trissel LA, Martinez JF.
Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride.
Ann Pharmacotherapy 1996 ; 30: 756-761.
517 Napló Letourneau M.
Visual compatibility of magnesium sulfate with narcotic analgesics.
Am J Hosp Pharm 1992 ; 49: 838-839.
519 Napló Poggi GL.
Compatibility of morphine tartrate admixtures in polypropylene syringes.
Aust J Hosp Pharm 1991 ; 21: 316.
660 Napló Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
813 Napló Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68.
814 Napló Johnson CE, VandenBussche HL, Chio CC, Jacobson PA.
Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration.
Am J Health-Syst Pharm 1999 ; 56: 164-169.
815 Napló Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905 Napló Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Napló Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
932 Napló Hor MMS, Chan SY, Yow KL, Lim LY, Chan E, Ho PC.
Stability of morphine sulphate in saline under simulated patient administration conditions.
J Clin Pharm Ther 1997 ; 22: 405-410.
1020 Napló Zuber DEL.
Compatibility of morphine sulfate injection and prochlorperazine injection.
Am J Hosp Pharm 1987 ; 44: 67.
1041 Napló Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1057 Napló Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Napló Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1079 Napló Stevenson JG, Patriarca C.
Incompatibility of morphine sulfate and prochlorperazine edisylate in syringes.
Am J Hosp Pharm 1985 ; 42: 2651.
1135 Napló Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1228 Napló Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
1232 Napló Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1276 Napló Shiffman E, Walker SE, Yoon T, Yeung M.
Stability and compatibility of morphine with bupivacaine.
Can J Hosp Pharm 1998 ; 51: 110-116.
1315 Napló Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1341 Napló Deeks T, Davis S, Nash S.
Stability of an intrathecal morphine injection formulation.
Pharm J 1983 ; 230: 495-497.
1410 Napló Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Napló Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Napló Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1438 Napló Souney PF, Solomon MA, Stancher D.
Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications.
Am J Hosp Pharm 1984 ; 41: 1840-1841.
1467 Napló Sitaram BR, Tsui M, Rawicki HB, Lam S, Courage P, Sitaram M, Chapman CB.
Stability and compatibility of baclofen and morphine admixtures for use in an implantable infusion pump.
Int J Pharm 1995 ; 118: 181-189.
1490 Napló Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1492 Napló LeBelle MJ, Savard C, Gagnon A.
Compatibility of morphine and midazolam or haloperidol in parenteral admixtures.
Can J Hosp Pharm 1995 ; 48: 155-160.
1495 Napló Nixon AR, O'Hare MCB, Chisakuta AM.
The stability of morphine sulphate and metoclopramide hydrochloride in various delivery presentations.
Pharm J 1995 ; 254: 153-155.
1496 Napló Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1512 Laboratórium Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015
1516 Laboratórium Ropivacaine (Naropeine®) - Summary of Product Characteristics
Mercury Pharmaceuticals Limited 2012
1603 Napló Bergquist PA, Manas D, Hunke WA, Reed RA.
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611 Napló Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 Napló Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Napló Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1665 Napló Öster Svedberg K, McKenzie J, Larrivee-Elkins C.
Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine.
J Clin Pharm Ther 2002 ; 21: 39-45.
1678 Napló Sitaram BR, Tsui M, Rawicki HB, Lam S, Sitaram M.
Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine.
Int J Pharm 1997 ; 153: 13-24.
1707 Napló Trissel LA, Xu QA, Pham L.
Physical and chemical stability of low and high concentrations of morphine sulfate with bupivacaine hydrochloride packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 70-73.
1708 Napló Xu QA, Trissel LA, Pham L.
Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 66-69.
1709 Napló Trissel LA, Xu QA.
Physical and chemical stability of morphine sulfate 5 mg/ml and 50 mg/ml packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 62-65.
1713 Napló Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Napló Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Napló Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1800 Napló Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803 Napló Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1810 Napló Lee G, Sabra K, Doyle N, Malley GO.
Stability of morphine sulphate in P.C.A.s.
EJHP 2003 ; 1:1-3.
1869 Napló Hildebrand KR, Elsberry DD, Hassenbusch SJ.
Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system.
J Pain Symptom Manage 2003 ; 25, 5: 464-471.
1925 Napló Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1944 Napló Hartman CA, Faria CE, Mago K.
Visual compatibility of bivalirudin with selected drugs.
Am J Health-Syst Pharm 2004 ; 61: 1774.
1948 Napló Classen AM, Wimbish GH, Kupiec TC.
Stability of admixtures containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system.
J Pain Symptom Manage 2004 ; 28, 6: 603-611.
1953 Napló Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1964 Napló Hartman CA, Baroletti SA, Churchill WW et al.
Visual compatibility of argatroban with selected drugs.
Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1968 Napló Williams OA, Middleton M, Henderson P, Reilly CS.
Stability of morphine and droperidol separately and combined, for use as an infusion.
Hosp Pharm Pract 1992 ; 2, 9: 597-600.
1974 Napló Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1982 Napló Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2064 Napló Nguyen-Xuan Tho, Griffiths W, Kern C, Van Gessel E, Bonnabry P.
Stability of morphine sulfate in polypropylene infusion bags for use in patient-controlled analgesia pumps for postoperative pain management.
Int J Pharm Compound 2006 ; 10: 69-73.
2086 Napló Sharley NA, Burgess NG.
Stability and compatibility of alfentanil hydrochloride and morphine sulfate in poypropylene syringes.
J Pharm Pract and Res 2003 ; 33: 279-281.
2108 Napló Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2123 Napló Lee G, Sabra K.
Stability of morphine sulphate in ANAPA Plus ambulatory infusion device and PEGA infusion sets.
EJHP Science 2006 ; 12, 4: 76-80.
2196 Napló Trissel LA, Trusley C, Ben M, Kupiec TC.
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration.
Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2233 Napló Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247 Napló Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2251 Napló Shields D, Montenegro R, Ragusa M.
Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration.
Neuromodulation 2005 ; 8, 4: 257-263.
2269 Napló Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2298 Napló Shields D.E, Aclan J, Szatkowski A.
Chemical stability of admixtures containing ziconotide 25 mcg/ml and morphine sulfate 10 mg/ml or 20 mg/ml during simulated intrathecal administration.
Int J Pharm Compound 2008 ; 12, 6: 553-557.
2305 Napló Bianchi F, Ginggen A, Tardy Y.
Stability and compatibility of drug mixtures in an implantable infusion system.
Anaesthesia 2008 63, 9: 972-978.
2322 Napló Donnelly R.F.
Physical Compatibility and Chemical Stability of Ketamine–Morphine Mixtures in Polypropylene Syringes.
Can J Hosp Pharm 2009 ; 62, 1
2350 Napló Roy J.J, Hildgen P.
Stability of morphine-ketamine in 0.9% sodium chloride injection packaged in syringes, plastic bags and MEDICATION CASSETTE Reservoirs.
Int J Pharm Compound 2000 ; 4, 3: 225-228.
3012 Napló Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3131 Napló Donnely RF, Wong K, Spencer J.
Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl.
Can J Hosp Pharm 2010 ; 63, 2: 154-155.
3152 Napló Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3184 Laboratórium
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005
3249 Napló Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3279 Napló Al-Tannak N.F, Cable C.G, McArthur D.A, Watson D.G
A stability indicating assay for a combination of morphine sulphate with levomepromazine hydrochloride used in palliative care.
J Clin Pharm Ther 2012 ; 37, 1: 71-73.
3434 Napló Kistner C, Ensom M.H.H, Decarie D, Lauder G, Carr R.R.
Compatibility and Stability of Morphine Sulphate and Naloxone Hydrochloride in 0.9% Sodium Chloride for Injection.
Can J Hosp Pharm 2013 ; 66, 3 : 167-170.
3474 Laboratórium Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3504 Laboratórium Parecoxib (Dynastat®) - Summary of Product Characteristics
Pfizer 2012
3507 Laboratórium Chirocaine - Summary of Product Characteristics
AbbVie 2013
3525 Laboratórium Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012
3531 Laboratórium Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3571 Napló Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3578 Laboratórium Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3593 Laboratórium Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics
Beacon Pharmaceuticals 2011
3595 Laboratórium Aciclovir - Summary of Product Characteristics
Hospira 2009
3599 Laboratórium Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013
3644 Laboratórium Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3675 Laboratórium Thiopental sodium - Summary of Product Characteristics
Archimedes Pharma UK Ltd 2015
3824 Napló Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3828 Poszter Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poszter So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3934 Laboratórium Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016
3948 Napló Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
3964 Napló Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3998 Napló Robert J, Sorrieul J, Rossignol E, Beaussart H, Kieffer H, Folliard C, Dupoiron D, Devys C.
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia.
Int J Pharm Compound 2017 ; 21:4 :347-351
4051 Napló Robert J, Sorrieul J, Kieffer H, Folliard C, Gibory V, Dupoiron D, Devys C.
Stability study of morphine and baclofen solution in polypropylene syringes.
Pharmaceutical Technology in Hospital Pharmacy 2017 ;2,4:173-180
4055 Napló Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Napló Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4303 Napló Anderson C, MacKay M.
Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes.
Pharmacy 2015 3, 379-385.
4319 Napló Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4380 Laboratórium Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4389 Napló Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4395 Poszter Hook R, Riss V, Neault A, Ma N, Law S, Walker S.E.
Stability of Morphine Solutions of 20, 40, 100 , 200 and 1,000 µg/mL in Syringes Following Dilution with 0.9% Sodium Chloride or D5W at Room Temperature (25°C).
Sunnybrook Health Sciences Centre 2020
4419 Napló Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4434 Napló Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4496 Napló Sorrieul J, Robert J, Dupoiron D, Devys, C.
Stability Study of Admixtures Combining Ziconotide With Morphine or Sufentanil in Polypropylene Syringes.
Neuromodulation 2020 ; 24, 7: 1145-1156.
4528 Napló Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4538 Napló Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K.
Compatibility of pentoxifylline and parenteral medications.
Archives of Disease in Childhood 2020 ; 105: 395-397.
4543 Napló Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4603 Napló Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Laboratórium Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4669 Napló Robert J, Sorrieul J, Dupoiron D, Jubier-Hamon S, Bienfait F, Visbecq A, Devys C.
Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration.
Neuromodulation 2021 : 1-16.
4730 Napló Sorrieul J, Robert J, Vincent L, Andre M, Bourcier B, Bienfait F, Jubier Hamon S, Dupoiron D, Devys C.
Stability of Morphine Sulfate-Clonidine and Sufentanil-Clonidine Mixtures.
Neuromodulation 2022
4742 Napló Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales